Anti-cytokine therapy in chronic destructive arthritis
- PMID: 11178124
- PMCID: PMC128880
- DOI: 10.1186/ar136
Anti-cytokine therapy in chronic destructive arthritis
Abstract
Tumor necrosis factor (TNF) and interleukin-1 (IL-1) are considered to be master cytokines in chronic, destructive arthritis. Therapeutic approaches in rheumatoid arthritis (RA) patients have so far focused mainly on TNF, which is a major inflammatory mediator in RA and a potent inducer of IL-1; anti-TNF therapy shows great efficacy in RA patients. However, it is not effective in all patients, nor does it fully control the arthritic process in affected joints of good responders. Directed therapy for IL-1, with IL-1 receptor antagonist, mainly reduces erosions and is marginally anti-inflammatory. It is as yet unclear whether the limited effect is akin to the RA process or linked to suboptimal blocking of IL-1. Analysis of cytokine patterns in early synovial biopsies of RA patients reveals a marked heterogeneity, with variable staining of TNF and IL-1 beta, indicative of TNF-independent IL-1 production in at least some patients. Evidence for this pathway emerged from experimental arthritises in rodents, and is summarized in this review. If elements of the models apply to the arthritic process in RA patients, it is necessary to block IL-1 beta in addition to TNF.
Figures


Comment in
-
A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg.Arthritis Res. 2001;3(4):211-3; discussion 214-5. doi: 10.1186/ar302. Epub 2001 Apr 24. Arthritis Res. 2001. PMID: 11438037 Free PMC article.
Similar articles
-
Is there a rationale for combined TNF and IL-1 blocking in arthritis?Clin Exp Rheumatol. 2002 Sep-Oct;20(5 Suppl 27):S21-5. Clin Exp Rheumatol. 2002. PMID: 14989425 Review.
-
A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg.Arthritis Res. 2001;3(4):211-3; discussion 214-5. doi: 10.1186/ar302. Epub 2001 Apr 24. Arthritis Res. 2001. PMID: 11438037 Free PMC article.
-
Arguments for interleukin 1 as a target in chronic arthritis.Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i81-4. doi: 10.1136/ard.59.suppl_1.i81. Ann Rheum Dis. 2000. PMID: 11053095 Free PMC article. Review.
-
Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis.Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii29-33. doi: 10.1136/ard.2006.058529. Ann Rheum Dis. 2006. PMID: 17038468 Free PMC article. Review.
-
Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra.Arthritis Rheum. 1996 May;39(5):797-809. doi: 10.1002/art.1780390513. Arthritis Rheum. 1996. PMID: 8639177
Cited by
-
Immunomodulatory activity of a Chinese herbal drug Yi Shen Juan Bi in adjuvant arthritis.Indian J Pharmacol. 2010 Apr;42(2):65-9. doi: 10.4103/0253-7613.64489. Indian J Pharmacol. 2010. PMID: 20711367 Free PMC article.
-
Cytokines in rheumatoid arthritis.Curr Rheumatol Rep. 2002 Jun;4(3):208-17. doi: 10.1007/s11926-002-0067-0. Curr Rheumatol Rep. 2002. PMID: 12010605 Review.
-
K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis.Front Immunol. 2016 Jun 2;7:213. doi: 10.3389/fimmu.2016.00213. eCollection 2016. Front Immunol. 2016. PMID: 27313578 Free PMC article. Review.
-
Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?Arthritis Res Ther. 2005;7 Suppl 2(Suppl 2):S15-20. doi: 10.1186/ar1505. Epub 2005 Mar 16. Arthritis Res Ther. 2005. PMID: 15833144 Free PMC article. Review.
-
The effect of Ganoderma lucidum extract on immunological function and identify its anti-tumor immunostimulatory activity based on the biological network.Sci Rep. 2018 Aug 23;8(1):12680. doi: 10.1038/s41598-018-30881-0. Sci Rep. 2018. PMID: 30139984 Free PMC article.
References
-
- Ghivazzani SC, Kang R, Georgescu HI, Lechman ER, Jaffurs D, Engle JM, Watkins SC, Tindal MH, Suchanek MK, McKenzie LR, Evans CH, Robbins PD. Constitutive intraarticular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human RA. J Immunol. 1997;159:3604–3612. - PubMed
-
- Probert L, Plows D, Kontogeorgos G, Kollias G. The type I IL-1 receptor acts in series with TNF1 to induce arthritis in TNF1 transgenic mice. Eur J Immunol. 1995;25:1794–1797. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical